# An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

> **NCT01008696** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 217 (actual)

## Conditions studied

- Reflux Esophagitis

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT01008696
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2013-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01008696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01008696, "An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01008696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*